This trial now confirms the previously reported clinical utility of oral SM-88 in EWS and other high-risk sarcomas.HopES continues to enroll toward the planned total of 12 subjects to more precisely define its benefit in this ultra-orphan, extremely recalcitrant disease.SM-88 has exceeded pre-specified futility in both cohorts (EWS maintenance and Ss salvage).ECOG performance remained stable for all.There were no serious drug-related AEs.Stable disease was achieved in 75.0% (6/8 with available data).Prespecified futility stopping was exceeded (i.e., >1 of first 5 subjects/cohort) upon achieving clinical benefit in each.Highlights from abstract number e23505 released on May 19, 2021: Title: Phase II Study of SM-88 in Ewing’s and Other Sarcomas (Nasdaq: TYME) announced that its abstract featuring data from the Company’s investigational therapy, SM-88, has been selected for publication at the American Society of Clinical Oncology ( OTC:ASCO) Annual Meeting being held virtually June 4-8, 2021. Analysts have a BUY recommendation on the stock with a $9.5/share price target. The goal of the strategic review was to assess TYME’s current pipeline, explore additional development opportunities, examine drug development process and determine how best to maximize the efficiency of the Company’s capital expenditures. On June 10, 2021, TYME executive management team will provide an updated business plan derived from the conclusions of the Company’s comprehensive strategic review that was conducted over the past several months.TYME may use a portion of the net proceeds to acquire or invest in businesses, products and technologies that are complementary to its own. On February 8, 2021, TYME announced that it closed its previously announced registered direct offering of 40M shares of its common stock at a purchase price of $2.50/share.Proof-of-concept trials to start in 2H2020. When the patent was announced TYME jumped almost 300%. The company's TYME-19 patented COVID-19 therapy is formulated to overcome any mutations of the virus.Clinical results thus far from trials of SM-88 in multiple advanced cancers, including pancreatic, prostate, sarcomas, breast, and other cancers have demonstrated the significant potential of the company's CMBT pipeline.TYME's 2021 ASCO abstract for drug candidate SM-88 in Ewing and other sarcomas reveals stable disease was achieved in 75.0% (6/8 with available data) with no serious drug-related AEs.I am a retired (early) petroleum and chemical engineers with several patents in crude oil refining and gas treating. I've lived and or visited over 50 countries in all continents. The stock is still down more than 50% year-to-date, although the boost helped it move in the right direction.I look for undervalued stocks with significant upside in energy, biotech, and technology. The stock had closed at around $1.22 per share by day’s end on Wednesday, which is the price it opened at today–the stock market was not open yesterday in observation of Independence Day. TYME stock is soaring about 22.5% on Friday afternoon following the news, which brought the price of the stock up to $1.50 per share. “We are increasingly encouraged that SM-88 has the potential to be a new treatment approach for late-stage pancreatic patients,” he added. Tyme Technologies said before the open that data from the study of SM-88 as an oral monotherapy revealed that the median overall survival of patients was 6.4 months, which compares favorably next to historical trials that showed survival of 2.0 to 2.5 months. “We believe that these outcomes further justify advancing the development of SM-88,” said Chief Medical Officer Giuseppe Del Priore. This led to trading volume increasing to more than 4.1 million shares, which is more than six times the full-day average. biotechnology company revealed that it had amassed positive updated data regarding its phase 2 study of SM-88, which is a treatment designed to help out patients with pancreatic cancer.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |